NCT06657131 Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer
| NCT ID | NCT06657131 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Heinrich-Heine University, Duesseldorf |
| Condition | Prostate Cancer After a Radical Treatment |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2026-11-30 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Following numerous retrospective studies and Phase-3-Studies with promising results, \[18F\]PSMA-1007 has been approved by european authorities. Therefore, it is a growing deployment of this diagnostic method anticipated. This study aims to investigate the diagnostic performance and clinical impact in a real-world-evidence in the context of regular clinical care. The evidence generated by this approach is supposed to assist in optimizing the management of prostate cancer patients.
Eligibility Criteria
Inclusion Criteria: * Informed Consent * Conduct of \[18F\]PSMA-1007 PET Imaging in the context of regular clinical care Exclusion Criteria: * Technical Flaws in the acquisition protocol
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.